ArticleBMC cardiovascular disorders2026
Temporal trends and disparities in US mortality with co-listed atrial fibrillation and gastrointestinal bleeding-related mortality, 1999-2020.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Efficacy of Rebamipide, Pantoprazole, and Their Combination for Gastroprotection in Patients with Atrial Fibrillation Receiving Direct Oral Anticoagulants: The Randomized REGATA Study.Medical sciences (Basel, Switzerland) · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral anticoagulants (OACs) effectively reduce stroke and mortality in patients with atrial fibrillation (AF), but their use increases the risk of gastrointestinal (GI) bleeding. The combined mortality burden from deaths in which AF and GI bleeding are co-listed has not been comprehensively characterized. This study evaluated national trends and demographic disparities in AF- and GI bleeding–related mortality from 1999 to 2020.
methodsMortality data were obtained from the CDC WONDER database for U.S. residents from 1999 to 2020. Deaths were included only when both AF and GI bleeding were recorded anywhere on the death certificate as underlying or contributing causes. Crude and age-adjusted mortality rates (AAMR) per 100,000 population were calculated, and Joinpoint regression estimated annual percent changes (APC).
resultsDeaths involving AF and GI bleeding increased from 1,486 in 1999 to 4,855 in 2020. AAMR rose from 0.55 to 1.16 per 100,000, with an accelerated rise between 2010 and 2020 (APC = 5.65%, p < 0.05). Males showed higher AAMR than females (AAPC = 3.61% vs. 2.83%), and White populations had the highest rates, while American Indian/Alaska Natives had the lowest. Nonmetropolitan areas showed faster increases than metropolitan ones (AAPC = 4.20% vs. 2.88%), with the central and western regions experiencing the steepest growth. Mortality was highest among older adults.
conclusionsAF- and GI bleeding–related mortality more than doubled from 1999 to 2020, disproportionately affecting elderly men, rural populations, and western U.S. regions. Targeted preventive strategies are essential to mitigate these rising disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.